Arcutis Biotherapeutics Inc (NASDAQ: ARQT) open the trading on Wednesday, with great promise as it jumped 0.11% to $8.75, before settling in for the price of $8.74 at the close. Taking a more long-term approach, ARQT posted a 52-week range of $1.76-$15.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 303.42% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -48.07%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 39.52%. This publicly-traded company’s shares outstanding now amounts to $114.97 million, simultaneously with a float of $97.27 million. The organization now has a market capitalization sitting at $1.01 billion. At the time of writing, stock’s 50-day Moving Average stood at $10.07, while the 200-day Moving Average is $6.51.
Arcutis Biotherapeutics Inc (ARQT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arcutis Biotherapeutics Inc’s current insider ownership accounts for 15.40%, in contrast to 84.57% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’24, this organization’s Director bought 21,052 shares at the rate of 9.50, making the entire transaction reach 199,994 in total value, affecting insider ownership by 8,785,284. Preceding that transaction, on Mar 04 ’24, Company’s insider sold 14,903 for 11.12, making the whole transaction’s value amount to 165,739. This particular insider is now the holder of 874,533 in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 12/31/2023 suggests? It has posted -1.31 earnings per share (EPS) beating the forecaster’s viewpoint (set at -1.28) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
Arcutis Biotherapeutics Inc’s EPS increase for this current 12-month fiscal period is 39.52% and is forecasted to reach -1.42 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 9.80% through the next 5 years, which can be compared against the -48.07% growth it accomplished over the previous five years trading on the market.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Let’s observe the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). It’s Quick Ratio in the last reported quarter now stands at 6.80. The Stock has managed to achieve an average true range (ATR) of 0.83.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
[Arcutis Biotherapeutics Inc, ARQT] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 9.69% While, its Average True Range was 0.79.
Raw Stochastic average of Arcutis Biotherapeutics Inc (ARQT) in the period of the previous 100 days is set at 61.26%, which indicates a major rise in contrast to 6.65% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 88.32% that was lower than 103.69% volatility it exhibited in the past 100-days period.
